Mechanism of MJ 1999-induced blockade of neuromuscular transmission.
D000813:Anilides / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000818:Animals; D003964:Diaphragm / Q000187:drug effects; D004357:Drug Synergism; D004837:Epinephrine / Q000494:pharmacology; D066298:In Vitro Techniques; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D009388:Neostigmine / Q000494:pharmacology; D009469:Neuromuscular Junction / Q000187:drug effects*; D009638:Norepinephrine / Q000494:pharmacology; D010643:Phenoxybenzamine / Q000494:pharmacology; D011189:Potassium Chloride / Q000494:pharmacology; D051381:Rats; D011955:Receptors, Drug; D013390:Succinylcholine / Q000494:pharmacology; D013451:Sulfonic Acids / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D013565:Sympatholytics / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D013566:Sympathomimetics / Q000494:pharmacology; D009435:Synaptic Transmission / Q000187:drug effects; D013757:Tetraethylammonium Compounds / Q000494:pharmacology; D014043:Tolazoline / Q000494:pharmacology; D014403:Tubocurarine / Q000494:pharmacology; D015016:Yohimbine / Q000494:pharmacology
D000813:Anilides; D011955:Receptors, Drug; D013451:Sulfonic Acids; D013565:Sympatholytics; D013566:Sympathomimetics; D013757:Tetraethylammonium Compounds; D010643:Phenoxybenzamine; D015016:Yohimbine; D009388:Neostigmine; D011189:Potassium Chloride; D014043:Tolazoline; D013390:Succinylcholine; D007545:Isoproterenol; D014403:Tubocurarine; D009638:Norepinephrine; D004837:Epinephrine